Canopy Growth provides fourth-quarter results and operational updates.
Canopy Growth Corporation (NYSE:CGC) today announced its financial results for the fourth quarter and full twelve-month fiscal year ended March 31, 2020. The Company is also sharing details of its new strategic plan aimed at winning in priority markets and categories and executing a path to profitability. All financial information in this press release is reported in millions of Canadian dollars, unless otherwise indicated. The fourth quarter and full twelve-month fiscal year 2020 financial results presented in this press release have been prepared in accordance with U.S. GAAP.
I am excited to implement our strategy reset and organization redesign over the course of fiscal 2021. David Klein CEO
"Through the COVID-19 pandemic, we have worked hard to ensure the health and well-being of our teams and customers and the continuity of our business. During this time, our team has rolled out our exciting new cannabis-infused beverages and vape products in Canada and a portfolio of CBD products in the US," shared CEO David Klein. "True to key priorities that I have outlined for Canopy, we have taken steps to align our capacity with the current market demand and focus our resources against the core markets with the largest and most tangible near-term profit opportunity."
Added Klein, "I am excited to implement our strategy reset and organization redesign over the course of fiscal 2021. We have a renewed strategic focus and a clear change agenda that is already underway. We are building what we believe is the best cannabis company in the world by putting the consumer at the heart of everything we do and are realigning our organization to be faster and more agile."
Strategic and Organizational Update
Canopy Growth's overall strategy is to unleash the full potential of cannabis, capture sizable market share in focus categories and markets and execute a path to profitability to build sustainable, long-term shareholder value.
The Company no longer strives to be the first to every market, but strives to the best and become a leading consumer insights and product development company in select priority markets, that matches products and consumer preferences in the cannabis space. To achieve this, Canopy Growth will focus on:
- Becoming a relentlessly consumer-centric organization by building world-class consumer insights and analytics, coupled with focused, leading-edge R&D and innovation to produce a differentiated product portfolio that will delight consumers. The Company will bring these products to the hands of consumers through best-in-class sales execution;
- Markets and product categories with the highest and most tangible profit opportunities in the near term. Core markets will be Canada, US and Germany with focus on recreational and medical. To capture future opportunities in emerging markets and categories outside the core, Canopy Growth will deploy an asset-light approach;
- Driving quality in all aspects of our operation and be positioned to deliver the right product at the right time at the right price from the right facility; and
- Continuing to lead the industry and set industry standards. This includes spearheading the next phase of the cannabis industry evolution and shaping how the industry evolves. The Company will continue to give back to neighbors and communities through its Grow Good Together initiatives.
Canopy Growth expects Fiscal 2021 to be a transition year as the Company resets its strategic focus, rolls out a new organizational design, and implements a comprehensive operational and supply chain productivity program. Given this, as well as the significant COVID-19 related uncertainties that exist, the Company is withdrawing its previously communicated milestones for achieving positive Adjusted EBITDA and Net Income. Depending on the impacts of COVID-19, Canopy Growth may provide new metrics by which to measure the Company's performance in the second half of fiscal 2021.
Fourth Quarter Fiscal 2020 Corporate Financial Highlights
- Revenues: Net revenue in Q4 2020 decreased 13% versus Q3 2020 driven primarily by lower Canadian recreational revenue.
- Gross margin: Reported gross margin, including one-time restructuring and other charges, was (85%). Adjusted gross margin, excluding one-time restructuring and other charges and inventory step-up costs, was 42% in Q4 2020, representing an increase of 1,100 bps from Q3 2020. Adjusted gross margin performance in Q4 2020 was positively impacted by higher facility utilization and growth in high margin international medical cannabis sales.
- Operating expenses: SG&A expenses in Q4 2020 increased 17% over Q3 2020 driven primarily by a combined $15 million increase in General & Administrative and Sales & Marketing expenses.
- Net Loss: Net loss of $1.3 billion in Q4 2020, primarily driven by impairment and restructuring charges, other impairment charges which were primarily identified during our annual impairment testing, and other non-cash fair value changes.
- Adjusted EBITDA: Adjusted EBITDA loss of $102 million in Q4 2020, a $5 million wider loss versus Q3 2020 driven by lower sales and higher operating expenses.
- Cash Position: Gross cash balance was $2.0 billion at March 31, 2020, down from $2.3 billion at the end of Q3 2020 reflecting the EBITDA loss, capital investments and mergers and acquisitions activities.
- Restructuring and Impairment Costs: In line with our previous announcement (March 4, 2020), we recorded a pre-tax restructuring and impairment charge of $743 million in Q4 2020, of which $28 million is estimated to be a cash charge. Additionally, we recorded impairment charges of $100 million Q4 2020, which were primarily identified during our annual impairment testing process.
Business & Operational Highlights
- UL certified Tokyo Smoke Luma pod-based vape devices, Luma "Go" pods and Luma "Pause" pods are available in the Canadian recreational market.
- Ready to Drink beverages under Tweed and Houseplant brands, representing a total of three SKUs, are available in the Canadian recreational market.
- Company has expanded offering of Hemp-derived CBD products with the launch of a line of First & Free topical creams in select states in the US and the launch of This Works' line of clinically-proven CBD Booster skin products in the United Kingdom, Germany and select states in the US.
- On May 1, 2020, an indirect wholly-owned subsidiary of Constellation Brands (NYSE: STZ) exercised warrants for approximately C$245 million, representing approximately 5.1% of our issued and outstanding common shares.
Fourth Quarter and Fiscal Year 2020 Financial and Operational Review
- Recreational B2B sales in Q4 2020 decreased 31% from Q3 2020 as growth in soft gels, oils, and Cannabis 2.0 products was more than offset by an overall decline in flower and pre-roll joints.
- Recreational B2C sales in Q4 2020 decreased 14% from the prior quarter due to the expected off-peak seasonal demand decline and the closure of corporate-owned retail stores late in the quarter in response to COVID-19.
- Medical sales in Q4 2020 remained consistent quarter over quarter (Q3 2020 vs. Q4 2020).
- C3 revenue in Q4 2020 increased 10% over Q3 2020.
- Germany cannabis sales increased 14% in Q4 2020 over Q3 2020 benefiting from improved supply and increased demand.
- International cannabis revenue accounted for 24% of total cannabis revenues in Q4 2020.
- This Works sales in Q4 2020 were consistent with seasonally strong Q3 2020.
- Storz & Bickel vaporizer revenue decreased over Q3 2020 due to seasonal decline.
- BioSteel Sports Nutrition revenue decreased by 20% over Q3 2020 due to expected seasonal decline and reduction of thirty-party distribution and retail in response to COVID-19.
To learn more about Canopy Growth, visit the company HQ here.
Disclaimer: Past performance is not an indicator of future performance.
& Keep Up to Date
Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!